Values as of: 2025-03-18
COMMON STOCK | Medical Devices |
Last Closing
USD 19.36Change
-0.23 (-1.17)%Market Cap
USD 2.10BVolume
0.92MAnalyst Target
USD 79.57Verdict
Verdict
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Company Website : https://www.novocure.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| DXCM | DexCom Inc |
-0.65 (-0.91%) |
USD 34.53B |
| PODD | Insulet Corporation |
-1.16 (-0.44%) |
USD 19.12B |
| MASI | Masimo Corporation |
-4.62 (-2.67%) |
USD 10.18B |
| BRKR | Bruker Corporation |
+0.20 (+0.43%) |
USD 7.16B |
| IRTC | iRhythm Technologies Inc |
-2.04 (-1.97%) |
USD 3.53B |
| PRCT | Procept Biorobotics Corp |
-2.00 (-3.39%) |
USD 3.27B |
| QDEL | Quidel Corporation |
-1.31 (-3.62%) |
USD 2.76B |
| TMDX | TransMedics Group Inc |
+1.30 (+1.92%) |
USD 2.27B |
| LIVN | LivaNova PLC |
-1.00 (-2.41%) |
USD 2.26B |
| TNDM | Tandem Diabetes Care Inc |
+0.35 (+1.78%) |
USD 2.11B |
| Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -35.03% | 22% | F | 15% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -35.03% | 22% | F | 15% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 42.98% | 88% | B+ | 88% | B+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 42.98% | 88% | B+ | 87% | B+ | ||
| Trailing 5 Years | |||||||
| Capital Gain | -69.69% | 34% | F | 17% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -69.69% | 34% | F | 16% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -6.54% | 35% | F | 25% | F | ||
| Dividend Return | -6.54% | 35% | F | 25% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 80.57% | 42% | F | 25% | F | ||
| Risk Adjusted Return | -8.12% | 37% | F | 29% | F | ||
| Market Capitalization | 2.10B | 91% | A- | 80% | B- | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
This stock has shown below median revenue growth in the previous 5 years compared to its sector
